Analysis of DGRO ETF's 52-Week Price Range
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy AMGN?
Source: NASDAQ.COM
- Price Range Analysis: DGRO ETF's 52-week low is $54.09 per share, with a high of $74.28, and a last trade at $69.61, indicating stability and investor confidence in the ETF's performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 349.000
Low
280.00
Averages
363.10
High
425.00
Current: 349.000
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump's Drug Pricing Policy Affects European Market Launches
- Launch Decline: According to GlobalData, the number of pharmaceutical launches in Europe has decreased by 35% in the first ten months following the implementation of the International Reference Pricing policy, indicating that Trump's Most Favored Nation pricing policy may lead drugmakers to delay or withdraw products, thereby impacting market competitiveness.
- Increased Withdrawals: In the ten months following Trump's executive order, the number of brands with at least one pack withdrawn from the European market rose by 43%, suggesting that drugmakers may face a dilemma between maintaining access in lower-priced EU markets and ensuring U.S. pricing integrity.
- Policy Impact Assessment: While other factors could contribute to changes in drug launches and withdrawals, GlobalData notes that this trend may serve as an early signal of the impact that the introduction of International Reference Pricing in the U.S. may have on European markets, raising concerns about patient access and affordability.
- Case Study: For instance, Amgen recently withdrew its cholesterol therapy Repatha from the Danish market, reflecting the strategic considerations drugmakers must navigate in response to pricing policies, which could influence their market positioning in Europe.
See More
FDA Warns of Liver Injury Risk Linked to Amgen's Tavneos
- Liver Injury Warning: The U.S. FDA has issued a warning regarding the risk of drug-induced liver injury associated with Amgen's Tavneos (avacopan), identifying 76 cases in its adverse events database that show reasonable evidence of a causal association, posing a significant threat to patient health.
- Serious Outcome Statistics: Among the 76 cases, 74 were classified as serious outcomes, including 54 hospitalizations and 8 deaths, indicating an urgent need to reassess the drug's safety to prevent future medical incidents and potential legal liabilities.
- Onset Time Analysis: The median time to onset of liver injury was 46 days (ranging from 22 to 140 days), suggesting that patients may experience severe health issues relatively soon after starting Tavneos, highlighting the need for enhanced monitoring by healthcare providers.
- Monitoring Recommendations: The FDA advises healthcare providers to initiate liver panel testing every two weeks during the first month of treatment, then monthly for the next five months, ensuring timely detection of potential liver damage to mitigate health risks for patients.
See More
Analysis of DGRO ETF's 52-Week Price Range
- Price Range Analysis: DGRO ETF's 52-week low is $54.09 per share, with a high of $74.28, and a last trade at $69.61, indicating stability and investor confidence in the ETF's performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and investment opportunities.
See More
Teva Receives FDA Approval for New Biosimilar Drug
- Biosimilar Approval: Teva Pharmaceutical's Ponlimsi (denosumab-adet) has received FDA approval as a biosimilar to Amgen's Prolia (denosumab), which is projected to generate approximately $4.4 billion in revenue in 2025, indicating Teva's potential in the osteoporosis treatment market.
- Increased Market Competition: As Prolia is Amgen's best-selling drug, Teva's approval may exert competitive pressure, potentially leading to a decline in Prolia's market share, which could adversely affect Amgen's revenue and market position.
- Regulatory Review Progress: Teva also announced that the FDA and the European Medicines Agency have agreed to review its biosimilar applications for Genentech and Novartis' Xolair (omalizumab), which reported sales of approximately $3.8 billion and $1.7 billion in 2025, respectively, showcasing Teva's expansion potential in respiratory disease treatments.
- Optimistic Industry Outlook: With the FDA relaxing testing rules for biosimilars, Teva's applications are likely to receive more support, potentially driving growth for other generic drug suppliers in the industry, thereby enhancing market competition and drug accessibility.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
Schwab U.S. Dividend ETF Reconstitutes, Increases Healthcare Holdings
- Healthcare Stock Increase: The Schwab U.S. Dividend ETF's recent annual reconstitution added two healthcare stocks, raising the sector's allocation from 15.4% to 18.9%, making it the second-largest sector, indicating a strategic focus on the growth potential of healthcare.
- High-Yield Stock Selection: During this reconstitution, UnitedHealth and Abbott Laboratories were added to the top ten holdings with allocations of 4% and 3.95%, respectively, reflecting the fund's preference for high-yield healthcare stocks, which is expected to enhance long-term investor returns.
- Dividend Growth Potential: The new holdings have an average dividend growth rate of 9.4%, surpassing the pre-reconstitution rate of 8.6%, and while the overall yield remains at 3.4%, the faster growth rate could lead to higher total returns for investors in the future.
- Strong Dividend Records: Both UnitedHealth and Abbott have robust dividend growth histories, with the former increasing its dividend by 52% over the past five years and the latter by 40%, showcasing the attractiveness and stability of the healthcare sector in dividend investing.
See More
Trump's Drug Pricing Policy Affects European Market Launches
- Launch Decline: According to GlobalData, the number of pharmaceutical launches in Europe has decreased by 35% in the first ten months following the implementation of the International Reference Pricing policy, indicating that Trump's Most Favored Nation pricing policy may lead drugmakers to delay or withdraw products, thereby impacting market competitiveness.
- Increased Withdrawals: In the ten months following Trump's executive order, the number of brands with at least one pack withdrawn from the European market rose by 43%, suggesting that drugmakers may face a dilemma between maintaining access in lower-priced EU markets and ensuring U.S. pricing integrity.
- Policy Impact Assessment: While other factors could contribute to changes in drug launches and withdrawals, GlobalData notes that this trend may serve as an early signal of the impact that the introduction of International Reference Pricing in the U.S. may have on European markets, raising concerns about patient access and affordability.
- Case Study: For instance, Amgen recently withdrew its cholesterol therapy Repatha from the Danish market, reflecting the strategic considerations drugmakers must navigate in response to pricing policies, which could influence their market positioning in Europe.
See More
FDA Warns of Liver Injury Risk Linked to Amgen's Tavneos
- Liver Injury Warning: The U.S. FDA has issued a warning regarding the risk of drug-induced liver injury associated with Amgen's Tavneos (avacopan), identifying 76 cases in its adverse events database that show reasonable evidence of a causal association, posing a significant threat to patient health.
- Serious Outcome Statistics: Among the 76 cases, 74 were classified as serious outcomes, including 54 hospitalizations and 8 deaths, indicating an urgent need to reassess the drug's safety to prevent future medical incidents and potential legal liabilities.
- Onset Time Analysis: The median time to onset of liver injury was 46 days (ranging from 22 to 140 days), suggesting that patients may experience severe health issues relatively soon after starting Tavneos, highlighting the need for enhanced monitoring by healthcare providers.
- Monitoring Recommendations: The FDA advises healthcare providers to initiate liver panel testing every two weeks during the first month of treatment, then monthly for the next five months, ensuring timely detection of potential liver damage to mitigate health risks for patients.
See More
Analysis of DGRO ETF's 52-Week Price Range
- Price Range Analysis: DGRO ETF's 52-week low is $54.09 per share, with a high of $74.28, and a last trade at $69.61, indicating stability and investor confidence in the ETF's performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and investment opportunities.
See More
Teva Receives FDA Approval for New Biosimilar Drug
- Biosimilar Approval: Teva Pharmaceutical's Ponlimsi (denosumab-adet) has received FDA approval as a biosimilar to Amgen's Prolia (denosumab), which is projected to generate approximately $4.4 billion in revenue in 2025, indicating Teva's potential in the osteoporosis treatment market.
- Increased Market Competition: As Prolia is Amgen's best-selling drug, Teva's approval may exert competitive pressure, potentially leading to a decline in Prolia's market share, which could adversely affect Amgen's revenue and market position.
- Regulatory Review Progress: Teva also announced that the FDA and the European Medicines Agency have agreed to review its biosimilar applications for Genentech and Novartis' Xolair (omalizumab), which reported sales of approximately $3.8 billion and $1.7 billion in 2025, respectively, showcasing Teva's expansion potential in respiratory disease treatments.
- Optimistic Industry Outlook: With the FDA relaxing testing rules for biosimilars, Teva's applications are likely to receive more support, potentially driving growth for other generic drug suppliers in the industry, thereby enhancing market competition and drug accessibility.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
Schwab U.S. Dividend ETF Reconstitutes, Increases Healthcare Holdings
- Healthcare Stock Increase: The Schwab U.S. Dividend ETF's recent annual reconstitution added two healthcare stocks, raising the sector's allocation from 15.4% to 18.9%, making it the second-largest sector, indicating a strategic focus on the growth potential of healthcare.
- High-Yield Stock Selection: During this reconstitution, UnitedHealth and Abbott Laboratories were added to the top ten holdings with allocations of 4% and 3.95%, respectively, reflecting the fund's preference for high-yield healthcare stocks, which is expected to enhance long-term investor returns.
- Dividend Growth Potential: The new holdings have an average dividend growth rate of 9.4%, surpassing the pre-reconstitution rate of 8.6%, and while the overall yield remains at 3.4%, the faster growth rate could lead to higher total returns for investors in the future.
- Strong Dividend Records: Both UnitedHealth and Abbott have robust dividend growth histories, with the former increasing its dividend by 52% over the past five years and the latter by 40%, showcasing the attractiveness and stability of the healthcare sector in dividend investing.
See More
